> ## Site index
> Full index of Peptides.build at https://peptides.build/llms.txt. Use it to discover every page.

# Tesamorelin vs Ipamorelin: Differences

Tesamorelin and ipamorelin compared: receptor, size, the research behind each, how each is prescribed, why they are blended, and FDA and sport status.

URL: https://peptides.build/learn/tesamorelin-vs-ipamorelin/

Comparison · Performance

# Tesamorelin vs ipamorelin: what is the difference?

Published October 12, 2026 · Educational, not medical advice

## Short answer

Tesamorelin and ipamorelin both prompt the pituitary to release growth hormone, but through different receptors: tesamorelin is a 44-amino-acid GHRH analog, ipamorelin a five-amino-acid ghrelin-receptor agonist. Tesamorelin has randomized trials in HIV-associated abdominal fat accumulation and a brand-name FDA approval in that one indication; ipamorelin has preclinical work and one negative surgical trial and is not FDA-approved for any use. Both are compounded here, and compounded medications are not FDA-approved. Both are prohibited in sport.

-   [What are tesamorelin and ipamorelin?](#what-each-is)
-   [How do tesamorelin and ipamorelin differ?](#differences)
-   [What does the research cover for each?](#research)
-   [How are tesamorelin and ipamorelin prescribed?](#prescribed)
-   [Are tesamorelin and ipamorelin FDA-approved or allowed in sport?](#status)
-   [FAQ](#faq)
-   [References](#references)

<table class="ln-facts pb-body"><caption class="pc-sr">Tesamorelin vs Ipamorelin quick facts</caption><tbody><tr><th scope="row">Key difference</th><td>GHRH-receptor analog (tesamorelin) versus ghrelin-receptor agonist (ipamorelin)</td></tr><tr><th scope="row">Size</th><td>Tesamorelin 44 amino acids; ipamorelin 5 amino acids</td></tr><tr><th scope="row">Evidence to date</th><td>Tesamorelin: randomized trials in HIV-associated abdominal fat accumulation. Ipamorelin: preclinical pharmacology and one negative trial in postoperative ileus</td></tr><tr><th scope="row">Form in this catalog</th><td>Tesamorelin alone or blended with ipamorelin; ipamorelin only inside blends. All supplied already reconstituted</td></tr><tr><th scope="row">Regulatory status</th><td>Compounded forms of both are not FDA-approved; branded tesamorelin is approved for one HIV-related indication, ipamorelin for nothing</td></tr><tr><th scope="row">Anti-doping</th><td>Both prohibited at all times (WADA S2: releasing factors and secretagogues)</td></tr><tr><th scope="row">Prescription units</th><td>Tesamorelin in milligrams, ipamorelin in micrograms</td></tr></tbody></table>

Evidence snapshot**What kind of research is cited for Tesamorelin vs Ipamorelin?**5 cited sources: 4 human clinical trials, 1 animal or lab study. Counts describe study type, not strength of result.

Sources cited for Tesamorelin vs Ipamorelin, by study type
| Study type | Sources |
| --- | --- |
| Human clinical trials | 4 |
| Other human studies | 0 |
| Animal and lab studies | 1 |
| Review articles | 0 |

## What are tesamorelin and ipamorelin?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone, the 44-amino-acid signal the hypothalamus sends to the pituitary. It keeps the natural sequence and adds a chemical group at one end that protects it from the enzyme that would otherwise break it down in minutes. It was developed under the code TH9507 and became a branded, FDA-approved injectable for one indication.

Ipamorelin is a much smaller molecule, a pentapeptide of five amino acids designed in the 1990s to trigger growth hormone release through a different receptor, the one later identified as the receptor for ghrelin. It was introduced in a 1998 paper as the first selective growth hormone secretagogue, and it has never been approved as a drug anywhere in the US.

## How do tesamorelin and ipamorelin differ?

Tesamorelin and ipamorelin differ in receptor, size, evidence, regulatory history and even in the units their prescriptions are written in. The receptor difference is the one the pairing is built on: tesamorelin acts on the GHRH receptor and ipamorelin on the ghrelin receptor, two separate inputs to the same pituitary cells. The evidence difference is the one patients should weigh most, because it is large.

Tesamorelin and ipamorelin side by side
| Feature | Tesamorelin | Ipamorelin |
| --- | --- | --- |
| Class | GHRH analog (releasing factor) | Ghrelin-receptor agonist (secretagogue) |
| Length | 44 amino acids | 5 amino acids |
| Human trials | Randomized trials and a pooled phase 3 analysis in HIV-associated abdominal fat accumulation | One randomized proof-of-concept trial in postoperative ileus; primary endpoint not met |
| FDA status | Branded product approved for one HIV-related indication; compounded form not approved | Not FDA-approved for any use |
| In this catalog | Alone, or blended with ipamorelin | Only inside blends with tesamorelin or CJC-1295 |
| Prescription units | Milligrams | Micrograms |
| WADA | S2, growth hormone releasing factors | S2, growth hormone secretagogues |

Prescribed, pre-mixed

## Get Tesamorelin / Ipamorelin prescribed, pre-mixed

 US-supervised · all 50 states

[Tesamorelin / Ipamorelin](https://peptides.build/protocols/tesamorelin-ipamorelin/)Blend: outside the HHS policy

**$183**/mo*$1,099 billed every 6 months*

Pay over time at checkout![Klarna](/media/payments/klarna.png)![Afterpay](/media/payments/afterpay.png)![Affirm](/media/payments/affirm.png)

Prescription required. Your provider decides if it is appropriate. Compounded medications are not FDA-approved.

## What does the research cover for each?

Tesamorelin research is the deeper of the two by a wide margin, and all of it sits in one clinical setting, HIV-associated abdominal fat accumulation. The studies cited here include a 2007 randomized trial of its metabolic effects in patients with HIV, a 2010 pooled analysis of two double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat, and a 2014 randomized trial measuring visceral fat and liver fat in that population. None of these studied adults without HIV.

Ipamorelin research is a 1998 preclinical pharmacology paper and a 2014 randomized proof-of-concept trial in postoperative ileus after bowel resection that did not meet its primary endpoint. No trial has tested the two compounds together, and no trial of either has examined performance or body-composition goals in healthy adults. The comparison, in short, is between a narrow but real randomized literature and almost none.

## How are tesamorelin and ipamorelin prescribed?

Tesamorelin is prescribed through Peptides.build on its own or in the Tesamorelin / Ipamorelin blend; ipamorelin is prescribed only inside that blend or the CJC-1295 / Ipamorelin blend. All are compounded medications: a licensed US provider reviews an online intake, writes a prescription if appropriate, and a licensed 503A pharmacy prepares and ships the vial already reconstituted with each peptide's strength on the label.

The choice between tesamorelin alone and the blend is the provider's, made against the patient's history and blood work. The blend fixes the ratio of the two peptides inside one vial, so it is not a way to add ipamorelin in an adjustable amount; a different ratio means a different vial. The free tesamorelin calculator on this site has a blend mode that works each peptide's strength separately. Doses are set by the provider and never published here.

## Are tesamorelin and ipamorelin FDA-approved or allowed in sport?

Compounded tesamorelin is not FDA-approved. Tesamorelin itself is FDA-approved under a brand name for one indication only, the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Ipamorelin is not FDA-approved for any use. Both reach patients here only as compounded medications prepared by a licensed 503A pharmacy, and compounded medications are not reviewed or approved by the FDA the way mass-manufactured drugs are.

Tesamorelin and ipamorelin are both prohibited in sport at all times. The World Anti-Doping Agency names tesamorelin under S2 among growth hormone releasing factors and ipamorelin under S2 among growth hormone secretagogues. The categories differ, the result does not. Drug-tested athletes should check with their governing body before either is prescribed.

Prescription, not research grade

## Prescribed Tesamorelin and Ipamorelin vs research peptides: what is different?

Prescribed Tesamorelin and Ipamorelin are not research chemicals. They are prescription medications: a licensed US provider reviews your intake first, and a licensed 503A pharmacy compounds each one for you by name. Vials sold online as “research use only” skip both steps. What you pay for here is that review, a pharmacy you can name, and a label that says what is in the vial.

A research seller’s certificate of analysis is a document the seller controls: it chooses the lab and the sample, and a PDF can be reused, edited or re-dated. No regulator checks it.

Prescribed Tesamorelin and Ipamorelin compared with research-use-only peptides
| Point | Prescribed through Peptides.build | Research use only |
| --- | --- | --- |
| Access | Online intake reviewed by a licensed US provider; prescribed only when appropriate. | No prescription and no clinical review of whether it suits you. |
| How it's labeled | A prescription medication compounded for you by name. | Commonly sold labeled “research use only, not for human consumption.” |
| Who prepares it | A licensed 503A US compounding pharmacy under state and federal oversight. | Unregulated suppliers, often with no verifiable chain of custody. |
| Testing | Third-party tested. | Certificates of analysis are self-reported when provided at all. |
| Purity and identity | Prepared to a prescription for a specific patient. | Purity, strength, and even identity are unverified by any independent party. |

This compares two care models, not two products. Compounded medications are not FDA-approved, and we do not claim otherwise. What a prescription adds is a licensed provider deciding whether a protocol is appropriate for you and a licensed pharmacy preparing it. [Read the full guide to research vs prescription peptides](https://peptides.build/learn/research-peptides-vs-prescription-peptides/).

Common questions

## Tesamorelin vs Ipamorelin FAQ

### Which has more evidence, tesamorelin or ipamorelin?

Tesamorelin, by a wide margin, but only in one setting: randomized trials in HIV-associated abdominal fat accumulation. Ipamorelin has preclinical pharmacology and a single randomized trial in postoperative ileus that did not meet its primary endpoint.

### Do tesamorelin and ipamorelin work the same way?

No. Both prompt the pituitary to release growth hormone, but tesamorelin acts on the GHRH receptor and ipamorelin on the ghrelin receptor. That is why they are sometimes prescribed together; the combination itself has not been tested in a trial.

### Can I get ipamorelin without tesamorelin?

Not on its own through this catalog. Ipamorelin is carried only inside the Tesamorelin / Ipamorelin and CJC-1295 / Ipamorelin blends. Tesamorelin is available alone.

### Is either one FDA-approved?

Tesamorelin is FDA-approved under a brand name for one indication only, excess abdominal fat in adults with HIV-associated lipodystrophy; the compounded form is not approved. Ipamorelin is not FDA-approved for any use. Compounded medications are not FDA-approved.

### Are tesamorelin and ipamorelin banned in sport?

Yes, both, at all times, under WADA S2. Tesamorelin is listed as a growth hormone releasing factor and ipamorelin as a growth hormone secretagogue. Drug-tested athletes should check with their governing body.

Prescribed, not mixed at home

## Tesamorelin / Ipamorelin through Peptides.build

A licensed US provider reviews a short online intake and decides whether a protocol is appropriate. A US 503A pharmacy prepares it already reconstituted, labels the concentration and ships it cold-chain. Dosing is set by the provider and is not published on this site.

-   [Tesamorelin / Ipamorelin protocol: pricing, who it is for, FAQ](https://peptides.build/protocols/tesamorelin-ipamorelin/)
-   [Tesamorelin protocol: pricing, who it is for, FAQ](https://peptides.build/protocols/tesamorelin/)
-   [All performance protocols compared](https://peptides.build/protocols/performance/)
-   [What is tesamorelin?](https://peptides.build/learn/what-is-tesamorelin/)
-   [What is ipamorelin?](https://peptides.build/learn/what-is-ipamorelin/)
-   [What is the Tesamorelin / Ipamorelin blend?](https://peptides.build/learn/what-is-tesamorelin-ipamorelin/)
-   [CJC-1295 vs tesamorelin: what is the difference?](https://peptides.build/learn/cjc-1295-vs-tesamorelin/)

Sources

## References

1.  Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. *New England Journal of Medicine*, 2007. [doi:10.1056/NEJMoa072375](https://doi.org/10.1056/NEJMoa072375)Study type: Randomized controlled trial (HIV-associated abdominal fat accumulation)
2.  Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. *Journal of Clinical Endocrinology and Metabolism*, 2010. [doi:10.1210/jc.2010-0490](https://doi.org/10.1210/jc.2010-0490)Study type: Pooled analysis of two phase 3 trials (HIV-associated abdominal fat accumulation)
3.  Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. *JAMA*, 2014. [doi:10.1001/jama.2014.8334](https://doi.org/10.1001/jama.2014.8334)Study type: Randomized controlled trial (HIV-associated abdominal fat accumulation)
4.  Ipamorelin, the first selective growth hormone secretagogue. *European Journal of Endocrinology*, 1998. [doi:10.1530/eje.0.1390552](https://doi.org/10.1530/eje.0.1390552)Study type: Preclinical pharmacology
5.  Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. *International Journal of Colorectal Disease*, 2014. [doi:10.1007/s00384-014-2030-8](https://doi.org/10.1007/s00384-014-2030-8)Study type: Randomized controlled trial (postoperative ileus; primary endpoint not met)

Citations are listed with their study type so the evidence can be weighed. Review articles summarize other studies; animal and in vitro findings do not describe outcomes in people.

This article is educational and is not medical advice. The compounded versions discussed here are not FDA-approved; compounded medications are not FDA-approved. No results are implied or guaranteed. Talk to a licensed provider about your own history before starting any protocol.